What makes this strategically important is that pharmaceutical supply chains are not judged only by whether a drug reaches the market. They are judged by whether every handoff is auditable, controlled, and trusted. In categories like oncology, even a small lapse in chain-of-custody discipline can create outsized financial, ethical, and patient-safety consequences. That inference is supported by the article’s emphasis on stricter tracking and accountability for high-value medicines.

The deeper lesson is that medical supply chains need a higher standard than ordinary inventory systems. Expensive, sensitive medicines require tighter serialization, clearer ownership at each node, stronger SOP adherence, and faster escalation when anomalies appear. Otherwise, “availability” can become misleading: the product may exist in the system, but the system itself may not be secure enough to guarantee proper handling and release. This is an inference from the article summary and the specific focus on supply-chain leaks.

Why it matters:
In healthcare supply chains, trust is part of the product. When traceability breaks down for high-value medicines, the damage is not only commercial, it can quickly become a patient-safety and governance issue.

Visit BusinessLine